Haisco Pharmaceutical Group Co. Ltd. has identified pyridone derivatives acting as integrin α4β7 (LPAM-1) antagonists reported to be useful for the treatment of Crohn’s disease and ulcerative colitis.
China Resources Pharmaceutical Research Institute (Shenzhen) Co. Ltd. has synthesized tricyclic heterocyclic compounds acting as protein arginine N-methyltransferase 5 (PRMT5) inhibitors reported to be useful for the treatment of cancer.
Scientists at Gwangju Institute of Science & Technology and JD Bioscience Inc. have disclosed 5-HT2A receptor antagonists reported to be useful for the treatment of cancer, hyperlipidemia, obesity, diabetes, arteriosclerosis, hepatic steatosis, fibrosis and hypertension.
South Korea’s Ministry of Food and Drug Safety announced Sept. 12 plans to significantly raise drug application fees for biosimilars but slash their review times starting next year.
Fudan University has described dihydroorotate dehydrogenase (DHODH) inhibitors reported to be useful for the treatment of bone disorders, immunological disorders, inflammatory disorders, viral infections and cancer.
Shanghai Yidi Biotechnology Co. Ltd. has divulged glucagon-like peptide 1 receptor (GLP-1R) agonists reported to be useful for the treatment of diabetes.
Rezubio Pharmaceuticals Co. Ltd. has disclosed drug conjugates comprising somatostatin receptor type 5 (SSTR5) antagonists covalently linked to a hydrophilic moiety through a linker reported to be useful for the treatment of type 2 diabetes.
RSS
